Regeneron pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (cscc) who are at a high risk of recurrence following surgery and radiation. Rhapsido (remibrutinib) is approved to treat chronic spontaneous urticaria resistant to antihistamine treatment. Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo
The fda evaluated libtayo under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions. In a significant step forward for skin cancer management, the u.s Review important safety info & full prescribing information including med guide.
